Claims
- 1. A hybrid vector for genetic material delivery comprising a nucleic acid molecule comprising:
(a) a helper-dependent adenoviral vector region comprising:
(i) a first and a second inverted terminal repeat, and (ii) an adenoviral packaging signal, wherein said adenoviral vector region substantially lacks sequences encoding adenoviral structural genes; and (b) a transposon region comprising:
(i) a first nucleic acid region encoding a transposon-derived protein or proteins, and (ii) a promoter region operably linked to said first nucleic acid region.
- 2. The hybrid vector of claim 1 wherein said transposon region further comprises a second nucleic acid region encoding said genetic material for delivery operably linked to said first nucleic acid region, wherein said second nucleic acid region can be integrated into the host cell genome during the process of transposition mediated by said transposon-derived proteins encoded by said first nucleic acid region.
- 3. The hybrid vector of claim 1 wherein said nucleic acid molecule is encapsidated by one or more helper adenovirus derived proteins for delivery as an adenovirus particle.
- 4. The hybrid vector of claim 1 wherein said first and second inverted terminal repeats comprise adenovirus serotype 2 or adenovirus serotype 5 sequences.
- 5. The hybrid vector of claim 1 wherein said adenoviral packaging signal is located adjacent to said first inverted terminal repeat.
- 6. The hybrid vector of claim 1 wherein said first nucleic acid region comprises a retrotransposon sequence.
- 7. The hybrid vector of claim 6 wherein said retrotransposon sequence comprises a first open reading frame encoding a nucleic acid binding protein and a second open reading frame encoding a reverse transcriptase operably linked to said promoter.
- 8. The hybrid vector of claim 6 wherein said promoter is a 5′ untranslated region of a retrotransposon.
- 9. The hybrid vector of claim 6 wherein said promoter is a viral promoter.
- 10. The hybrid vector of claim 9 wherein said promoter is an SV40 or a cytomegalovirus promoter.
- 11. The hybrid vector of claim 2 wherein said second nucleic region comprises sequences to the 3′ side of said first nucleic acid region.
- 12. The hybrid vector of claim 2 further comprising a polyadenylation site to the 3′ side of said second nucleic acid region.
- 13. The hybrid vector of claim 1 wherein said first nucleic acid region comprises a DNA transposon sequence.
- 14. The hybrid vector of claim 13 wherein said DNA transposon-derived sequences comprise an open reading frame encoding a transposase operably linked to said promoter.
- 15. The hybrid vector of claim 14 wherein said promoter is a viral promoter.
- 16. The hybrid vector of claim 15 wherein said promoter is an SV40 or a cytomegalovirus promoter.
- 17. The hybrid vector of claim 13 further comprising a second nucleic acid region comprising a nucleic acid molecule for delivery flanked by direct or inverted DNA transposon terminal repeat sequences.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a divisional of U.S. patent application Ser. No. 09/484,901 filed Jan. 18, 2000, which claims the benefit of provisional application Ser. No. 60/116,150 filed Jan. 15, 1999, the disclosure of which is incorporated by
GOVERNMENT SUPPORT
[0002] The government may have certain rights in this invention pursuant to grant no. 1R21DK054280-01 from the National Institutes of Health.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60116150 |
Jan 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09484901 |
Jan 2000 |
US |
Child |
10102610 |
Mar 2002 |
US |